Blog
Kisspeptin vs PT-141: Key Differences for Libido (2026)
Kisspeptin vs PT-141 compared: where each acts, what the human studies show for men and women, how fast each works, whether they are run together, dosing in units for both, and which suits which research.
Kisspeptin and PT-141 end up in the same basket for one reason: both are studied for sexual desire. The resemblance stops there. They come from different hormone families, act at different levels of the brain’s chain of command, run on different clocks, and only one of them is an approved drug.
Simms Research sells both as 10mg vials, Kisspeptin-10 at $74 and PT-141 at $64. Which one fits depends on what the research is after: the hormones that set the background, or the response on a given day.
What are kisspeptin and PT-141?
Kisspeptin is a natural hormone made in the hypothalamus. It was found in 1996 at Penn State’s medical school in Hershey, Pennsylvania, as a gene that stopped melanoma from spreading, and was named after Hershey’s Kisses. Its real job surfaced in 2003, when two research groups found that people born without a working kisspeptin receptor do not go through puberty on their own. The body makes it in several lengths; the vial holds kisspeptin-10, its final ten amino acids, the smallest fragment with full activity at the receptor.
PT-141 is bremelanotide, a synthetic ring of seven amino acids. It descends from Melanotan 2, the tanning peptide whose University of Arizona trials turned up erections as a side effect, and was reworked to pull far less on skin color. Palatin Technologies took it through trials, and the FDA approved it in June 2019 as Vyleesi, for premenopausal women with low sexual desire.
What is the difference between kisspeptin and PT-141?
Where each one acts. Kisspeptin starts the reproductive hormone cascade. It binds KISS1R on GnRH neurons; the GnRH they release reaches the pituitary, which answers with LH and FSH, and those set testosterone output in men and estrogen in women. Nothing in the vial is a sex hormone: kisspeptin only makes the body release more of its own, as far as the pituitary and the testes or ovaries can answer.
PT-141 skips the hormone cascade. It switches on the melanocortin receptors MC4R and MC3R in the hypothalamus, which are tied to desire and arousal, so its effect does not wait for LH or testosterone to move. Sildenafil-type drugs act on blood flow; PT-141 acts on the signal that comes first.
The two systems are not sealed off from each other. Kisspeptin also acts directly on the brain’s emotional and reward areas, which is where its desire research comes from, and a 2025 mouse study found MC4R, PT-141’s receptor, on kisspeptin neurons themselves, where it helps keep the reproductive hormone rhythm running. So PT-141 works on the response in the moment, kisspeptin on the hormones behind it, with some wiring shared between them.
Kisspeptin vs PT-141 side by side
Both compounds on one grid, with the Simms Research vials in the last row:
| Kisspeptin-10 | PT-141 | |
|---|---|---|
| What it is | The last 10 amino acids of a natural reproductive hormone | Bremelanotide, a 7-amino-acid ring developed from Melanotan 2 |
| Receptor | KISS1R (GPR54) on GnRH neurons | MC4R and MC3R, melanocortin receptors |
| Works on | LH and FSH, then testosterone or estrogen | Desire and arousal signals in the brain |
| Raises LH and testosterone | Yes, within the normal range | No, it works around them |
| Desire research in people | Single-visit brain-imaging trials of about 30 people each | Two 24-week trials in 1,267 women |
| Approval | None; still in clinical research | Vyleesi, US 2019, premenopausal women |
| Rhythm | Short pulses, daily or every other day | As needed, at most once a day |
| Half-life | About 4 minutes | About 2.7 hours |
| Most common side effect | None recorded in the human studies | Nausea, 40% in the phase 3 trials |
| Simms Research vial | 10mg, $74 | 10mg, $64 |
Kisspeptin vs PT-141 for libido: what the studies show
PT-141 has the bigger, longer trials; kisspeptin has the newer and more detailed look at what happens in the brain.
PT-141’s case rests on two 24-week phase 3 trials in 1,267 premenopausal women with low sexual desire, published in 2019. Taken as needed at 1.75mg, it raised scores on a desire scale that runs from 1.2 to 6 by 0.30 and 0.42 points more than placebo, and lowered distress about low desire in both trials. The count of satisfying sexual events did not separate from placebo, as Vyleesi’s label notes. Those results carry the only approval any desire peptide holds.
Kisspeptin’s case comes from one group at Imperial College London. In a 2017 study, 29 healthy young men given kisspeptin showed stronger activity in the brain’s emotional and reward areas while viewing sexual and couple-bonding images, and their negative mood eased. A 2020 follow-up found the same for scents and faces linked to attraction, most of all in men with the lowest sexual quality-of-life scores. Then came people with low desire: in a 2023 trial, 32 men showed shifts in the brain network that handles sexual cues, measured physical arousal up to 56% higher than on placebo, and more happiness about sex, and in a 2022 trial, 32 women showed changed processing of sexual cues and attractive faces.
Every one of those kisspeptin trials was a single 75-minute infusion of kisspeptin-54 into a vein, measured during the visit. None has run for weeks, and none used kisspeptin-10 under the skin. A 2026 review of peptides in sexual medicine put it plainly: bremelanotide is among the most clinically established, kisspeptin shows early promise.
PT-141 vs kisspeptin for men
For testosterone, kisspeptin; for a direct desire and arousal response, PT-141, though its research in men stopped short of an approval.
Kisspeptin is the one with the testosterone data. In 2011, a 22.5-hour kisspeptin-10 drip raised testosterone in healthy men by about 45%, keeping it inside the normal range, and in a 2026 study, men given kisspeptin-10 under the skin for 8 hours a day still showed raised LH on day 12.
PT-141 was tested in men before Palatin chose women: injected doses above 1mg produced an erectile response in healthy men, with no approval for men to follow. The PT-141 guide covers those trials and the doses.
Kisspeptin vs PT-141 for women
PT-141 is the one built for women: its approval, both phase 3 trials and its 1.75mg dose all come from premenopausal women with low desire. Kisspeptin’s research in women is promising but earlier, the 2022 brain-imaging trial above.
Kisspeptin also behaves differently in women. Its hormone effect depends on where in the menstrual cycle the dose lands: kisspeptin-10 barely moved LH early in the cycle and raised it clearly in the days before ovulation, and the combined pill erased it. The kisspeptin guide’s section on women goes through those studies. PT-141 does not work through those hormones, so the cycle day does not change its dose.
How long kisspeptin and PT-141 take to work
PT-141 takes about an hour. Kisspeptin moves its first hormone within minutes, and testosterone follows over the next hours.
PT-141’s blood levels peak 30 minutes to an hour after an injection, and the label asks for at least 45 minutes of lead time. Half of it clears in about 2.7 hours. How long the effect lasts, the label leaves open, and it caps use at one dose per 24 hours and eight per month; women in the trials took a median of 10 doses over 24 weeks.
Kisspeptin-10 works the other way round. LH peaked within 45 minutes in the injection studies, and the peptide itself is gone from the blood in minutes, so each draw is a brief pulse. What matters is the rhythm over weeks, because the receptor stops answering a signal that never lets up. In the same 2026 study, five days of nonstop kisspeptin-10 let LH and FSH fall back to placebo levels, while 8-hour daily runs kept them raised through day 12. That is why protocols give it as one pulse daily or on alternate days; kisspeptin cycle and pulsing covers the spacing.
Can you take kisspeptin and PT-141 together?
No study has paired them, but they do not compete: different receptors, different schedules and side effects that do not overlap.
Research protocols that run both treat them as two layers. Kisspeptin-10 goes in as a daily or every-other-day pulse to work on the hormone background; PT-141 sits on top as an occasional dose. Kisspeptin brings no blood-pressure effect into the mix: in a 2025 study of 95 volunteers, an active dose raised LH and left blood pressure, heart rate, cortisol and anxiety unchanged. PT-141’s small, passing rise in blood pressure is its own.
The one open question is the shared wiring. MC4R sits on kisspeptin neurons in mice, so PT-141 may nudge the hormone rhythm too, but no one has measured that in people.
Kisspeptin vs PT-141 side effects
Most draws of either pass without incident. What separates them is how often PT-141’s effects come, and how little kisspeptin’s record shows.
PT-141 has the larger record, from the phase 3 trials. Nausea hit 21% of women on the first dose and fell to about 3% on later ones, coming on within the hour and gone in about two; across 24 weeks, 40% of women reported it at some point. Flushing came in 20%, injection-site reactions in 13% and headache in 11%. Each dose nudges systolic pressure up by as much as 6 points, settling within 12 hours, and darker patches of skin appeared in 1% on the label’s eight-a-month ceiling.
Kisspeptin’s human studies recorded no side effects worth noting: none in the 2011 kisspeptin-10 study, none in either desire trial, and no change in blood pressure, heart rate or anxiety across 95 volunteers. Dosing sites mention brief warmth or flushing and redness where it went in. The one effect on record is the response wearing off under nonstop exposure, which spacing the pulses prevents.
Kisspeptin vs PT-141 dosage
Mixing is identical: each 10mg vial takes 2mL of bac water, which puts 500mcg of either peptide behind every 10 units of a U-100 syringe. The draws and the rhythm are what differ:
| Kisspeptin-10 | PT-141 | |
|---|---|---|
| Usual research draw | 100 to 200mcg (2 to 4 units) | 1.75mg (35 units), within 500mcg to 2mg |
| How often | Daily or on alternate days | As needed, at most once in 24 hours |
| Draws in 28 days | 28 at 100mcg a day | Up to 5 at 1.75mg; 2 or 3 at the trials’ pace |
| Cost | $74 per four weeks, about $79 per 30 days | $64 a vial, used inside 28 days |
A mixed vial keeps 28 days in the fridge, and that limit, not the powder, sets each vial’s life. A kisspeptin vial at 100mcg a day uses under a third of its 10mg before day 28; a PT-141 vial holds five 1.75mg doses, and only a twice-a-week schedule uses all five in time. The full charts are in the kisspeptin dosage guide and the PT-141 dosage chart; the peptide calculator handles any other dose, and how to reconstitute peptides covers the mixing. Simms Research’s Research Water, $20 for 10mL of bac water, makes five 2mL mixes, enough for both vials with water to spare, and storage before and after mixing is in the peptide refrigeration guide.
Which is better, kisspeptin or PT-141?
For desire and arousal, PT-141. For the hormones behind them, kisspeptin. Is kisspeptin better than PT-141? Only when the research is about LH, testosterone or the reproductive cycle, which PT-141 does not touch.
Choose PT-141 when the question is the response itself: desire and arousal, taken when wanted, at a dose with an approval and 24-week trials behind it. It works in about an hour whatever the hormone levels, and it is the cheaper vial. Expect nausea in the first draws.
Choose kisspeptin when the question sits upstream: testosterone through the body’s own LH in men, the cycle and ovulation in women, fertility work, or how the brain processes sexual and attraction cues. It runs as daily or every-other-day pulses, its side-effect record is nearly blank, and its desire evidence, though detailed, is still single-visit lab work.
Choose both when the research covers both layers, low desire with the hormone background in question. They run on separate schedules from separate vials, and nothing in either record argues against the pairing.
Frequently asked questions
Does kisspeptin actually work?
For hormones, yes: in men it has raised LH, and testosterone with it, in study after study, and in a 2014 IVF study a single dose matured eggs in women going through treatment. For desire, its brain-imaging and arousal results are real but come from single lab visits, not long trials.
How long does it take to feel the effects of kisspeptin?
Minutes for the hormone response, with LH peaking inside 45 and testosterone following over hours. The desire-related brain changes in the Imperial trials showed up during the 75-minute infusion itself.
What is better than PT-141?
For desire, no research peptide has more human evidence. Melanotan 2, its parent, reaches the same receptors plus the pigment one, so it tans as well (the Melanotan 1 vs 2 comparison covers it). Kisspeptin works a level up. Oxytocin, often grouped with the two, did no better than placebo in a 2015 trial of 30 women.